Christopher B. Ehrlich, Director at eFFECTOR Therapeutics, Inc. (EFTR), bought 6,000 shares at $5.00 ($31K) on 2022-02-04, disclosed to the SEC on 2022-02-07.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.15 | 5,000 | $26K | 83.7% |
| 2 | $5.00 | 1,000 | $5K | 16.3% |
| Total | $5.13 avg | 6,000 | $31K | 100% |
| Filing → |
| EFTR | BUY | 2022-02-22 | $13K | — | Filing → |
| EFTR | BUY | 2022-02-10 | $10K | — | Filing → |
| EFTR | BUY | 2022-01-31 | $27K | — | Filing → |